Decrease of serum sphingosine-1-phosphate levels in hemodialysis patients with secondary hyperparathyroidism treated with cinacalcet

Clin Nephrol. 2012 Jul;78(1):85-6. doi: 10.5414/cn107307.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Biomarkers / blood
  • Calcimimetic Agents / therapeutic use*
  • Chromatography, High Pressure Liquid
  • Cinacalcet
  • Down-Regulation
  • Female
  • Humans
  • Hyperparathyroidism, Secondary / blood
  • Hyperparathyroidism, Secondary / drug therapy*
  • Hyperparathyroidism, Secondary / etiology
  • Kidney Diseases / blood
  • Kidney Diseases / complications
  • Kidney Diseases / therapy*
  • Lysophospholipids / blood*
  • Male
  • Middle Aged
  • Naphthalenes / therapeutic use*
  • Renal Dialysis / adverse effects
  • Sphingosine / analogs & derivatives*
  • Sphingosine / blood
  • Treatment Outcome

Substances

  • Biomarkers
  • Calcimimetic Agents
  • Lysophospholipids
  • Naphthalenes
  • sphingosine 1-phosphate
  • Sphingosine
  • Cinacalcet